Tyra Biosciences, Inc.

TYRASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1863127

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$80.1M	$62.5M	$43.0M	$20.6M	$7.2M
Operating Expenses	$104.2M	$79.9M	$58.9M	$26.3M	$9.3M
Operating Income (Loss)	-$104.2M	-$79.9M	-$58.9M	-$26.3M	-$9.3M
Nonoperating Income (Expense)	$17.7M	$10.8M	$3.6M	-$6.0K	-$39.0K
Income Tax Expense (Benefit)	$0.00	$0.00	$2.0K	$1.0K	$1.0K
Net Income (Loss) Attributable to Parent	-$86.5M	-$69.1M	-$55.3M	-$26.3M	-$9.3M
Earnings Per Share, Basic	-$1.51	-$1.62	-$1.32	-$1.91	—
Earnings Per Share, Diluted	-$1.51	-$1.62	-$1.32	-$1.91	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$363.6M	$225.9M	$266.2M	$306.7M	$16.0M
Assets, Current	$347.5M	$211.7M	$257.3M	$304.1M	$15.3M
Cash and Cash Equivalents, at Carrying Value	$92.0M	$58.0M	$251.2M	$302.2M	$15.2M
Liabilities	$20.4M	$21.6M	$8.4M	$5.0M	$2.0M
Liabilities, Current	$14.6M	$15.3M	$5.7M	$3.6M	$1.9M
Accounts Payable, Current	$590.0K	$4.7M	$1.1M	$599.0K	$664.0K
Stockholders' Equity Attributable to Parent	$204.3M	$257.8M	$301.7M	-$13.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$69.8M	-$50.1M	-$50.3M	-$23.7M	-$7.8M
Net Cash Provided by (Used in) Investing Activities	-$98.4M	-$144.6M	-$559.0K	-$645.0K	-$312.0K
Net Cash Provided by (Used in) Financing Activities	$202.1M	$1.5M	$632.0K	$311.3M	$23.4M
Payments to Acquire Property, Plant, and Equipment	$664.0K	$770.0K	$559.0K	$661.0K	$312.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)